US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals
Executive Summary
Agency will work past generic goal dates if approval can be achieved quickly thereafter, but now must create policy defining criteria for those situations.
You may also be interested in...
Generics Review Data From US FDA Reveals Positives, Negatives For Industry
While a decline in complete response letters in FY 2023 is good, the continued drop in ANDA submissions could be a bad sign for the industry’s long-term health, a former FDA official worries.
Generics Review Data From US FDA Reveals Positives, Negatives For Industry
While a decline in complete response letters in FY 2023 is good, the continued drop in ANDA submissions could be a bad sign for the industry’s long-term health, a former FDA official worries.
Missed ANDA Nods Mostly Due To 'Imminent Approval'
US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.